Vital Signs - Pulmonary Drug Delivery: Going Beyond Lung Diseases

 

Regular Price: USD 1,500

Special Price USD 1,050

30% OFF

* Required Fields

Regular Price: USD 1,500

Special Price USD 1,050

PAY BY INVOICE

Be the first to review this product

This issue of Vital Signs, released on June 21, 2010, provides a strategic analysis of trends in pulmonary drug delivery outside of respiratory diseases. Additionally, a company spotlight is provided for ZIOPHARM Oncology, a company focused on the research and development of small molecule therapies for the treatment of cancer. Reimbursement and regulatory news from the FDA is also provided for the week of May 31, 2010.

Table of Contents

Vital Signs - Pulmonary Drug Delivery: Going Beyond Lung DiseasesVital Signs: 21 June 2010This week's issue:




Related Research

Release Date : 08-Sep-17

Region : North America

Release Date : 22-Aug-17

Region : North America

Release Date : 08-Aug-17

Region : North America

Release Date : 31-Jul-17

Region : North America

Release Date : 27-Jul-17

Region : North America

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.